A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.10006 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 10006-10006 ◽

Author(s):

J. C. Trent ◽

K. Wathen ◽

M. von Mehren ◽

B. L. Samuels ◽

A. P. Staddon ◽

...

Keyword(s):

Gastrointestinal Stromal Tumor ◽

Phase Ii ◽

Phase Ii Study ◽

Stromal Tumor ◽

Imatinib Resistant

Download Full-text

Regorafenib as second line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST): A phase II study

Annals of Oncology ◽

10.1093/annonc/mdz339.023 ◽

2019 ◽

Vol 30 ◽

pp. vi88

Author(s):

Yoichi Naito ◽

Toshihiko Doi ◽

Tsuyoshi Takahashi ◽

Toshihiro Kudo ◽

Narikazu Boku ◽

...

Keyword(s):

Gastrointestinal Stromal Tumor ◽

Phase Ii ◽

Phase Ii Study ◽

Stromal Tumor ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Imatinib Resistant

Download Full-text

Systemic steroid treatment for severe skin rash induced by imatinib in patients with gastrointestinal stromal tumor (GIST): A phase II study

Annals of Oncology ◽

10.1093/annonc/mdy299.018 ◽

2018 ◽

Vol 29 ◽

pp. viii583

Author(s):

E. Kim ◽

M.-H. Ryu ◽

S.R. Park ◽

M.Y. Beck ◽

W.J. Lee ◽

...

Keyword(s):

Gastrointestinal Stromal Tumor ◽

Skin Rash ◽

Phase Ii ◽

Phase Ii Study ◽

Steroid Treatment ◽

Stromal Tumor ◽

Systemic Steroid

Download Full-text

A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.10007 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 10007-10007 ◽

Author(s):

S. George ◽

M. von Mehren ◽

M. C. Heinrich ◽

Q. Wang ◽

C. L. Corless ◽

...

Keyword(s):

Gastrointestinal Stromal Tumor ◽

Phase Ii ◽

Phase Ii Study ◽

Stromal Tumor ◽

Multicenter Phase

Download Full-text

Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib

Annals of Oncology ◽

10.1093/annonc/mdx387.006 ◽

2017 ◽

Vol 28 ◽

pp. v322-v323 ◽

Author(s):

Y. Kurokawa ◽

T. Doi ◽

A. Sawaki ◽

Y. Komatsu ◽

M. Ozaka ◽

...

Keyword(s):

Heat Shock Protein ◽

Gastrointestinal Stromal Tumor ◽

Phase Ii ◽

Phase Ii Study ◽

Heat Shock Protein 90 ◽

Download Full-text

Systemic Steroid Treatment for Imatinib‐Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study

The Oncologist ◽

10.1634/theoncologist.2019-0953 ◽

2020 ◽

Vol 25 (11) ◽

Author(s):

Eo Jin Kim ◽

Min‐Hee Ryu ◽

Sook Ryun Park ◽

Mo Youl Beck ◽

Woo Jin Lee ◽

...

Keyword(s):

Gastrointestinal Stromal Tumor ◽

Skin Rash ◽

Phase Ii ◽

Phase Ii Study ◽

Steroid Treatment ◽

Stromal Tumor ◽

Systemic Steroid

Download Full-text

Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib

Annals of Oncology ◽

10.1093/annonc/mdy299.019 ◽

2018 ◽

Vol 29 ◽

pp. viii583

Author(s):

H. Cho ◽

M.-H. Ryu ◽

B.J. Kim ◽

Y. Park ◽

Y.-S. Na ◽

...

Keyword(s):

Gastrointestinal Stromal Tumor ◽

Phase Ii ◽

Phase Ii Study ◽

Download Full-text

Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.10050 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 10050-10050 ◽

Author(s):

A. D. Van Den Abbeele ◽

Y. Tanaka ◽

T. Locascio ◽

C. Sakellis ◽

M. C. Heinrich ◽

...

Keyword(s):

Gastrointestinal Stromal Tumor ◽

Phase Ii ◽

Fdg Pet ◽

Standard Therapy ◽

Phase Ii Study ◽

Stromal Tumor ◽

Multicenter Phase ◽

Pet Ct ◽

Download Full-text

Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

Case Medical Research ◽

10.31525/ct1-nct04193553 ◽

2019 ◽

Author(s):

Keyword(s):

Gastrointestinal Stromal Tumor ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Stromal Tumor ◽

Metastatic Gist ◽

Download Full-text

Living Donor Liver Transplantation for Imatinib‐Resistant Gastrointestinal Stromal Tumor Liver Metastases: A New Therapeutic Option in Transplant Oncology

Liver Transplantation ◽

10.1002/lt.25844 ◽

2020 ◽

Vol 26 (10) ◽

pp. 1373-1374

Author(s):

Maria Abbondanza Pantaleo ◽

Massimo Del Gaudio ◽

Matteo Ravaioli ◽

Matteo Cescon ◽

Margherita Nannini

Keyword(s):

Liver Transplantation ◽

Liver Metastases ◽

Gastrointestinal Stromal Tumor ◽

Living Donor ◽

Living Donor Liver Transplantation ◽

Therapeutic Option ◽

Stromal Tumor ◽

Donor Liver ◽

Donor Liver Transplantation ◽

Imatinib Resistant

Download Full-text

Abstract A217: The HSP90 inhibitor AT13387 demonstrates potent antitumor activity in both imatinib-sensitive and imatinib-resistant gastrointestinal stromal tumor models.

10.1158/1535-7163.targ-11-a217 ◽

2011 ◽

Author(s):

Tomoko Smyth ◽

Thomas Van Looy ◽

Jayne Curry ◽

Agnieszka Wozniak ◽

Ana Rodriguez-Lopez ◽

...

Keyword(s):

Antitumor Activity ◽

Gastrointestinal Stromal Tumor ◽

Hsp90 Inhibitor ◽

Stromal Tumor ◽

Tumor Models ◽

Imatinib Resistant

Download Full-text